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Background and objective: In the current meta-analysis of randomized controlled trials (RCTs), the effects of
probiotic supplementation on mental health, biomarkers of inflammation and oxidative stress in patients with
psychiatric disorders were assessed.
Methods: The following databases were search up to February 2019: PubMed, Scopus, Web of Science, Google
scholar and Cochrane Central Register of Controlled Trials.
Results: Twelve studies were included in the current meta-analysis. The findings demonstrated that probiotic
supplementation resulted in a significant reduction in Hamilton Depression Rating Scale (HAMD) [Weighted
Mean Difference (WMD): -9.60; 95 % CI: -10.08, -9.11]. In addition, a significant reduction in C-reactive protein
(CRP) (WMD: -1.59; 95 % CI: -2.22, -0.97), interleukin 10 (IL-10) (WMD: -0.29; 95 % CI: -0.48, -0.11) and
malondialdehyde (MDA) levels (WMD: -0.38; 95 % CI: -0.63, -0.13) was found after probiotics supplementation.
No significant change was seen in Beck Depression Inventory (BDI) score (WMD: -11.17; 95 % CI: -24.99, 2.65),
tumor necrosis factor-α (TNF-α) (WMD: -0.12; 95 % CI: -0.20, -0.05), IL-1B (WMD: -0.34; 95 % CI: -1.43, 0.74),
IL-6 (WMD: 0.03; 95 % CI: -0.32, 0.38), nitric oxide (NO) (WMD: -0.54; 95 % CI: -2.16, 1.08), glutathione (GSH)
(WMD: 46.79; 95 % CI: -17.25, 110.83) and total antioxidant capacity (TAC) levels (WMD: 15.21; 95 % CI:
-59.96, 90.37) after probiotics supplementation.
Conclusion: Overall, the current meta-analysis demonstrated that taking probiotic by patients with psychiatric
disorders had beneficial effects on HAMD, CRP, IL-10 and MDA levels, but it did not affect BDI score, other
markers of inflammation and oxidative stress.
1. Introduction
Psychiatric disorders are known as major public health problems
which cause distress and disability and exits in many forms, including
schizophrenia, anxiety and mood disorders.1,2 These conditions can co-
occur with a wide variety of central nervous system (CNS) and meta-
bolic disorders.3 It is estimated that more than 29.2 % of adults ex-
perienced a common mental disturbance within their lifetime.4 Poor
mental health is associated with a considerable lower quality of life,
and high economic and social burden.5 Previous studies have indicated
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that the mortality rate among people suffering from mental disorders is
two times higher than the general population.6 The pathological path-
ways involved in the development of Parkinson's disease (PD) are not
completely known, but it is now well-accepted that brain tissue is
particularly susceptible to increased inflammation and oxidative
stress.7 Increased peripheral inflammatory markers, elevated produc-
tion of reactive oxygen species (ROS), reduced activity of antioxidant
systems and decreased efficiency in repairing mechanisms are asso-
ciated with neurological and mental disorders such as major depressive
disorders (MDD) and Alzheimer's disease (AD).8,9 In addition, several
psychiatric and neurological diseases may be associated with intestinal
dysbiosis which influence the function of CNS via the gut brain axis.10
Probiotic bacteria provide various health benefits, exert anti-in-
flammatory effects, ameliorate oxidative stress, modulate host meta-
bolism and brain function.11 Currently, a meta-analysis demonstrated
that probiotic supplementation in healthy subjects led to a significant
improvement in preclinical psychological symptoms of anxiety, de-
pression and stress.12 In addition, a meta-analysis conducted by Mazidi
et al.,13 probiotic administration significantly decreased C-reactive
protein (CRP) levels, bud had no significant effect on interleukin 10 (IL-
10) and tumor necrosis factor alpha (TNF-α) levels. Another meta-
analysis indicated that probiotics could effectively protect the intestinal
mucosa, physical and biological barrier by reducing CRP and secretary
immunoglobulin A in people with colorectal cancer after the operation,
but did not affect IL-6 levels.14 However, a recent meta-analysis in
women with polycystic ovary syndrome did not affect any significant
change in CRP concentrations after probiotic supplementation.15 In
addition, several randomized controlled trials (RCTs) have investigated
the efficacy of probiotics on biomarkers of inflammation and oxidative
stress in patients with psychiatric disorders, but the results are incon-
sistent. Akkasheh et al. 16 reported that probiotic supplementation for 8
weeks to patients with MDD significantly improved Beck Depression
Inventory (BDI), high-sensitivity C-reactive protein (hs-CRP) and glu-
tathione (GSH) levels, but did not influence other biomarkers of in-
flammation and oxidative stress. Furthermore, a 12-week probiotic and
vitamin D co-supplementation in patients with schizophrenia alleviated
some indicators of inflammation and oxidative stress.17 However, the
sample size of these trials was small, dosage and formulation of pro-
biotic supplements were different, the quality of studies was variable,
and the results were controversial. It is proposed that the reduction in
biomarkers of inflammation and oxidative stress following probiotics
supplementation might be due to their effects on increasing glutathione
(GSH) concentrations and scavenging superoxide and hydroxyl radicals,
decreasing gene expression of IL-6 in adipocytes, and decreasing adip-
osity.18,19
Despite numerous RCTs, we are aware of no meta-analysis of RCTs
on the effect of probiotic supplementation on parameters of mental
health, and biomarkers of inflammation and oxidative stress in patients
with psychiatric symptoms. This meta-analysis was conducted to sum-
marize the available evidence of RCTs to determine the effects of pro-
biotic supplementation on parameters of mental health, and biomarkers
of inflammation and oxidative stress in patients with psychiatric dis-
orders.
2. Methods
2.1. Search strategy
Eligible RCTs were identified using Cochrane Library, PubMed,
Scopus, Web of Science and Google scholar databases for relevant ar-
ticles published until February 2019, and by manually searching the
reference list of the retrieved articles. Databases of International
Standard Randomized Controlled Trial Number Register and Meta-
register for RCTs were also searched for all ongoing trials. Studies re-
trieved that evaluated the impact of probiotic and/or synbiotic sup-
plementation on parameters of mental health, and biomarkers of
inflammation and oxidative stress by using the following MeSH and text
words: patients ["psychotic disorder" OR "depressive disorders" OR
"mental disorder" OR "mental health" OR "mood" OR "depression" OR
"attention deficit disorder with hyperactivity" OR "attention deficit
hyperactivity disorder (ADHD)" OR "autism spectrum disorder" OR
"Tourette syndrome" OR "obsessive-compulsive disorder" OR "anxiety
disorder" OR "AD" OR "schizophrenia" OR "bipolar disorder"], inter-
vention [("probiotic and/or synbiotic" OR "symbiotic")], and outcomes
["Hamilton Depression Rating Scale (HAMD)" OR "Beck Depression
Inventory (BDI)" OR "IL-1B" OR "IL-6" OR "TNF-α" OR "CRP" OR "nitric
oxide (NO)" OR "malondialdehyde (MDA)" OR "total antioxidant capa-
city (TAC)" OR "glutathione (GSH)"]. Additional manual searches in-
cluding reference lists of related studies; former review studies were
reviewed to increase sensitivity in search strategy. Studies included to
this meta-analysis had the following criteria: 1) original trials, 2)
human trials, 3) intervention and control groups received of probiotic
and/or synbiotic supplementation and placebo, respectively and 4) the
trials reported mean changes or mean difference of body composition
and/or metabolic profiles with standard deviation (SD) for the inter-
vention and control groups.
2.2. Data extraction and quality assessment
Two authors (EA and HM) independently extracted the data and
assessed its quality using standard forms and the Cochrane
Collaboration risk of bias tool,20,21 respectively. This tool is based on
information on the following domains: randomization generation, al-
location concealment, blinding of subjects and outcome assessment,
incomplete outcome data, and selective outcome reporting, and other
sources of bias. When there was disagreement among them, it resolved
by third author (AG). Eligible studies were abstracted: 1) first authors’
name 2) publication year 3) age, sex and body composition and/or
metabolic profiles of study participants and associated measures of
variance 4) study location 5) number of subjects in the intervention and
control groups 6) study design 7) duration of the intervention.
3. Data analysis
3.1. Heterogeneity and publication biases
The statistical heterogeneity across the results of the included stu-
dies was tested using chi-square test,22 and quantified by the I2 sta-
tistic.23 Publication bias was assessed by the funnel plot and tested for
statistical significance using the Egger's test.24
3.2. Summary measures
We calculated the mean difference for the influence of probiotic
supplementation on parameters of mental health, and biomarkers of
inflammation and oxidative stress for each included studies. The change
score approach was used to obtain the effect sizes, because the corre-
lations between baseline and end measurements were more than 1/2.25
A meta-analysis was performed to obtain the summary measures for the
effect of probiotic supplementation on parameters of mental health, and
biomarkers of inflammation and oxidative stress using the inverse
variance method. The random effects model was used to report the
pooled mean difference with 95 % confidence interval (CI). P-va-
lues< 0.05 were considered as statistically significant. Statistical ana-
lyses were performed using both Stata version 11.0 (Stata Corp., Col-
lege Station, TX) and Review Manager 5.3.
4. Results
4.1. Study characteristics
Seventeen effect sizes from twelve studies were included in the
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current systematic review and meta-analysis. Flow-diagram studies are
shown in Fig. 1. Studies were published between 2016 and 2019.
General characteristics of included studies are presented in Table 1. A
total of 656 participants, including 330 individuals in the intervention
and 326 individuals in the control groups, were enrolled in these stu-
dies. Duration of studies was varied between 6 and 12 weeks. Probiotic
supplements were mainly consisted of Lactobacillus or Bifidobacter
strains. In some cases, miscellaneous strains of bacteria and in the
others a combination of multiple strains were used as the intervention.
Use of probiotic capsules, sachets, and probiotic-containing foods were
the most predominant forms of supplementation in the included stu-
dies.
4.2. Findings for the effects of probiotic supplementation on parameters of
mental health
Combining eight effect sizes from 4 studies, we found a significant
reduction in HAMD following probiotic supplementation [Weighted
Mean Difference (WMD): -9.60; 95 % CI: -10.08, -9.11] (Fig. 2A). Due
to the high between-studies heterogeneity (I2= 99.7 %), we stratified
studies based on participants’ age (< 40/≥40 years) (Table 2). This
stratification did not change the overall finding. A pooled analysis of 3
studies about the effects of probiotics on BDI failed to find a significant
association (WMD: -11.17; 95 % CI: -24.99, 2.65) (Fig. 2B).
4.3. Findings for the effects of probiotic supplementation on inflammatory
markers
4.3.1. Effects of probiotic supplementation on CRP levels
A significant reduction in CRP concentrations was found after sup-
plementation with probiotics, as shown when we combined data from 5
available studies (WMD: -1.59; 95 % CI: -2.22, -0.97) (Fig. 2C), which
remained significant after subgroup analysis based on study sample size
(n<50/n≥50) (Table 2).
4.3.2. Effects of probiotic supplementation on TNF-α levels
Serum levels of TNF-α was reduced after supplementation with
probiotics, as resulted from combination of data from 4 available stu-
dies (WMD: -0.12; 95 % CI: -0.20, -0.05) (Fig. 2D). The same findings
were reached from subgroup analysis based on study sample size in
studies with a sample size of< 50, whereas, no significant effect was
seen among those with a sample size of ≥50 (WMD: -0.15; 95 % CI:
-0.58, 0.27) (Table 2).
4.3.3. Effects of probiotic supplementation on other inflammatory markers
Findings from the polled analysis of available studies showed no
significant effects of probiotic supplementation on levels of IL-1B
(WMD: -0.34; 95 % CI: -1.43, 0.74) (Fig. 2E), IL-6 (WMD: 0.03; 95 % CI:
-0.32, 0.38) (Fig. 2F) and NO (WMD: -0.54; 95 % CI: -2.16, 1.08)
(Fig. 2G); however, it caused a significant reduction in IL-10 levels
(WMD: -0.29; 95 % CI: -0.48, -0.11) (Fig. 2H).
4.4. Findings for the effects of probiotic supplementation on biomarkers of
oxidative stress
4.4.1. Effects of probiotic supplementation on GSH levels
Probiotic supplementation did not influence GSH levels in a polled
analysis of 5 studies (WMD: 46.79; 95 % CI: -17.25, 110.83) (Fig. 2J).
Subgroup analysis based on study sample size showed a significant
increase in GSH levels following probiotic supplementation among
studies with a sample size of≥50 (WMD: 59.56; 95 % CI: 30.87, 88.26)
(Table 2).
4.4.2. Effects of probiotic supplementation on MDA and TAC levels
The current meta-analysis demonstrated that probiotic supple-
mentation led to a significant reduction in MDA levels (WMD: -0.38; 95
% CI: -0.63, -0.13) (Fig. 2K). Combining data from 5 studies, no sig-
nificant change was found in TAC following consumption of probiotic
supplements (WMD: 15.21; 95 % CI: -59.96, 90.37) (Fig. 2L). However,
a significant reduction in TAC was seen after probiotic supplementation
in studies a sample size of< 50 (WMD: -81.64; 95 % CI: -121.25,
-42.02). Otherwise, probiotic supplementation resulted in a significant
increase in TAC among studies that recruited ≥50 individuals (WMD:
60.25; 95 % CI: 32.39, 88.10) (Table 2).
5. Discussion
In this meta-analysis, for the first time, we pooled data from avail-
able evidence of probiotic supplementation in participants suffered
from psychiatric disease. The present study exhibited that taking pro-
biotic supplements by patients with psychiatric disorders improved
HAMD, CRP, IL-10 and MDA levels, but did not affect BDI score, and
other markers of inflammation and oxidative stress.
6. Effects on parameters of mental health
Psychiatric disease is a complicated condition in which mood and
mental disorder lead to impaired individual function.2 In addition, in-
creased inflammatory markers and disrupted antioxidant defense
system could be identified in patients with different types of psychiatric
illnesses.26 Our findings revealed that probiotic supplementation im-
proved HAMD, but did not affect BDI score in patients with psychiatric
disorders. In a meta-analysis study by McKean et al.,12 probiotic sup-
plementation led to a significant reduction in anxiety, depression and
stress symptoms in healthy population. In addition, Huang et al. 27
demonstrated that probiotic consumption decreased depression scale
score in both healthy and MDD patients. However, in a recent meta-
analysis, probiotic supplementation was not effective in decreasing
poor mood symptoms in healthy individuals and patients with mental
disorder.28 Depressive symptoms account as one of the strongest pre-
dictors of quality of life in mental disorders.29 It is documented that
Fig. 1. Literature search and review flowchart for selection of studies.
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there is a significant association between BDI score and health-related
quality of life.30 In addition, a variety of unfavorable health behaviors
are related to depressive disorders.31 The exact mechanism by which
probiotics exert beneficial psychological effects are not elucidated, it is
postulated that probiotic bacteria promote biosynthesis of neuro-
transmitters, including gamma-aminobutyric acid, norepinephrine,
serotonin, dopamine, and acetylcholine which influence brain activity
and improve mood symptoms.32 In addition, probiotic consumption
increases the expression of brain-derived neurotrophic factor which
plays an important role in neural plasticity, memory, neural health and
has antidepressant effects.33 Moreover, probiotics modify intestinal
microbiota composition and inflammatory immune system reactions
which has a great impact on the gut-brain axis and possibly modulates
emotional state.34
7. Effects on inflammatory markers
In the present study, we demonstrated that the use of probiotic
supplements in patients with psychiatric disorders reduced CRP and IL-
10 levels, but did not influence other inflammatory markers. A meta-
analysis conducted by Aqaeinezhad et al.,35 ptobiotic supplementation
in patients with rheumatoid arthritis decreased CRP concentrations.
Mazidi et al. 13 reported that probiotic administration significantly
improved CRP, while did not change IL-10 and TNF-α concentrations.
In addition, a meta-analysis indicated that probiotic consumption in
patients with colorectal cancer reduced CRP values; while IL-6 levels
remained unchanged.14 However, results of the present study differ
from findings of a previous meta-analysis study by Samah et al. 36 that
found no significant effect of probiotics on CRP concentrations. The
peripheral inflammatory signals can reach the brain and amplify in-
flammation in CNS which results in altered brain performance in areas
mediating mood and cognition.9 In addition, inflammatory state
Fig. 2. Meta-analysis mental health and biomarkers of inflammation and oxidative stress weighted mean difference estimates for A) HAMD, B) BDI, C) CRP, D) TNF-
α, E) IL-1B, F) IL-6, G) NO, H) IL-10, J) GSH, K) MDA and L) TAC in the probiotics supplements and placebo groups (CI= 95 %).
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influence the synthesis of adverse tryptophan cathabolites which pro-
mote apoptosis, hippocampal damage and disrupt neural plasticity.37 It
is indicated that increased levels of inflammatory markers such as TNF-
α in depression contributes to treatment resistance.38 Moreover, some
evidence suggested that anti-inflammatory treatments may have
antidepressant properties.39 The role of probiotics in alleviating in-
flammatory response can be explained by production of short chain
fatty acids which decrease enzymatic synthesis of CRP in the liver,19
and modulation the activity of Toll-like receptor, nuclear factor kappa-
B, and mitogen-activated protein kinase pathways which reduce the
Fig. 2. (continued)
Table 2
Subgroup analyses for the effects of probiotic supplementation on parameters of mental health and biomarkers of inflammation and oxidative stress among patients
with psychiatric disorders.
Variables Subgroups Number of effect sizes Pooled WMD 95 % CI I2 (%) Between-study I2 (%)
HAMD Participants’ age < 40 year 2 −1.69 −2.37, −1.02 81.0 <0.001
≥40 year 2 −18.10 −18.80, −17.41 98.8
CRP Study sample size n< 50 2 −0.97 −1.32, −0.63 00.0 <0.01
n≥ 50 3 −1.87 −2.35, −1.39 27.8
GSH Study sample size n< 50 2 −22.13 −65.15, 20.90 90.2 <0.01
n≥ 50 3 59.56 30.87, 88.26 71.5
TAC Study sample size n< 50 2 −81.64 −121.25, −42.02 81.6 <0.001
n≥ 50 3 60.25 32.39, 88.10 46.1
TNF-α Study sample size n< 50 2 −0.12 −0.20, −0.04 57.9 0.88
n≥ 50 2 −0.15 −0.58, 0.27 0.0
HAMD: Hamilton Depression Rating Scale; BDI: Beck Depression Inventory; CRP: C-reactive protein; GSH: Glutathione; IL-1B: Interleukin-1Beta; IL-6: Interleukin-6;
IL-10: Interleukin-10; TNF-α: Tumor necrosis factor-alpha; NO: Nitric oxide; TAC: Total antioxidant capacity; MDA: Malondialdehyde.
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expression of pro-inflammatory cytokines.40
8. Effects on biomarkers of oxidative stress
Results of our study indicated that probiotic supplementation sig-
nificantly reduced MDA levels, bud did not affect other biomarkers of
oxidative stress. However, when we stratified studies by the partici-
pants’ age, a significant increase in GSH levels was seen after probiotic
supplementation in adults. In addition, intake of probiotics resulted in a
significant increase in TAC in studies with adults as well as those with a
sample size of ≥50. Several clinical studies have investigated the ef-
fects of probiotics on oxidative stress in patients with mental illness.
Two studies showed that probiotic supplementation reduced MDA
concentrations in subjects with AD 41 and schizophrenia.17 In addition,
Akkasheh et al. 16 reported that probiotic supplementation led to a
significant increase in TAC levels. However, in a meta-analysis con-
ducted by Aqaeinezhad et al.,35 it was reported that probiotic supple-
mentation did not affect TAC and MDA levels in RA patients. Dysre-
gulation in oxidative balance leads to tissue damage and has been
implicated in the pathogenesis of neuropsychiatric disorders.42 De-
creased antioxidant capacity and increased ROS cause damage to pro-
tein, DNA, and membrane fatty acids and thereby results in cell apop-
tosis, neurodegeneration and brain volumetric changes. Enhanced
oxidative status also contributes to triggering autoimmune responses in
mental disorders,26 and provokes lipid peroxidation which increases the
risk of atherosclerosis in depressed individuals.43 Furthermore, elevated
MDA levels can influence the metabolism of serotonin by inhibiting the
ligand binding site of serotonin.44 Moreover, a significant inverse cor-
relation has been reported between antioxidants and the severity of
clinical symptoms of psychiatric disorders and some studies reported
that antioxidant therapy improved mental outcomes in these condi-
tions.45 Probiotic supplementation may lead to the modulation of oxi-
dative stress by several mechanisms, including metal ion chelating
ability, regulating ROS levels by application of their antioxidant en-
zyme system, generation antioxidant metabolits such as GSH, reg-
ulating the antioxdant system of host, preventing the genration of hy-
droxy radicals and mediation signaling of Nrf2, protein kinase C and
other antioxidant signaling pathways.46
9. Conclusions
Overall, the current meta-analysis demonstrated that taking pro-
biotic by patients with psychiatric disorders had beneficial effects on
HAMD, CRP, IL-10 and MDA levels, but did not affect other markers of
inflammation and oxidative stress.
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